The current study provides a strong rationale to target mesothelin in advanced lung adenocarcinoma and suggest that clinical trials of mesothelin-directed therapies in lung cancer should focus on patients with KRAS mutations, the most commonly mutated oncogene in NSCLC and one which has proven intractable even in the era of targeted therapy. This evidence concerns the gene MSLN and lung cancer.